NASDAQ$AFYA
Afya Limited · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Afya Q2 2025: R$919M revenue (+13% YoY) as medical education platform expands
Afya Limited reported Q2 2025 results through unaudited interim financial statements filed on Form 6-K. Net revenue reached R$919.4 million, up 13.5% from R$809.9 million in Q2 2024, driven by its integrated medical education platform spanning undergraduate programs, continuing education, and medical practice solutions. Gross profit rose to R$576.7 million from R$495.0 million, and operating income increased to R$285.2 million from R$230.8 million. Net income totaled R$176.5 million versus R$162.2 million a year earlier, with basic EPS of R$1.90 compared to R$1.76. The company maintained strong cash of R$1.1 billion and continued investing in digital health assets including iClinic and Medicinae.
- Q2 revenue of R$919.4M grew 13.5% YoY; H1 revenue reached R$1.86B (+15% YoY)
- Q2 net income of R$176.5M and basic EPS of R$1.90 vs R$1.76 prior year
- Operating income rose to R$285.2M from R$230.8M on higher gross margin
- Cash and equivalents of R$1.10B; intangible assets reflect ongoing M&A in med-ed
- Brazilian Real functional currency; segment mix spans undergrad, continuing ed, and practice solutions
Headline financials
Revenue & EPS history
Afya · Revenue · Quarterly
R$919M
Revenue by segment
Afya · R$1.01B total across 3 segments · Q1 2026
- UndergraduateR$892M+7.9%87.9%
- Continuing EducationR$78.9M+11.0%7.8%
- Medical Practice SolutionsR$43.4M—4.3%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2025
-0.7%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+1.2%
Avg return
30 days after
52%
11 / 21 earnings
Positive
+8.9%
Q1 2020
Best reaction
-20.8%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.4% | +1.6% | +3.4% | |
| Q3 2026 | +1.2% | +2.2% | +0.7% | |
| Q2 2025 | +3.4% | +0.2% | +4.6% | |
| Q1 2025 | -3.3% | -2.1% | -9.7% | |
| Q3 2024 | -7.8% | -6.2% | -10.7% | |
| Q2 2024 | -1.8% | -2.4% | -14.1% | |
| Q1 2024 | -1.9% | +0.2% | -13.1% | |
| Q4 2023 | +3.3% | +2.2% | -18.9% | |
| Q3 2023 | +3.3% | +8.6% | +22.1% | |
| Q1 2023 | +7.3% | +6.8% | +16.6% | |
| Q4 2022 | -8.5% | -1.9% | +11.0% | |
| Q3 2022 | -4.5% | -3.7% | +2.2% | |
| Q4 2021 | -9.4% | -7.3% | +0.8% | |
| Q3 2021 | -10.9% | -2.7% | +0.5% | |
| Q1 2021 | +8.5% | +9.2% | +24.2% | |
| Q4 2020 | +6.3% | +7.1% | +4.7% | |
| Q3 2020 | -0.7% | -2.8% | -0.7% | |
| Q1 2020 | +8.9% | +9.9% | +26.3% | |
| Q4 2019 | +6.4% | +5.9% | -4.1% | |
| Q3 2019 | +3.5% | +6.5% | -1.5% | |
| Q2 2019 | -20.8% | -22.3% | -19.7% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro